{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:53:28Z","timestamp":1757314408306,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13555-022-00853-4","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T11:28:19Z","timestamp":1669548499000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-232X","authenticated-orcid":false,"given":"Wayne","family":"Gulliver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4462-1856","authenticated-orcid":false,"given":"Baojin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5342-7409","authenticated-orcid":false,"given":"Christian","family":"Jossart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1986-3194","authenticated-orcid":false,"given":"Sonia","family":"Montmayeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7907-6400","authenticated-orcid":false,"given":"Russel","family":"Burge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4150-4569","authenticated-orcid":false,"given":"Catherine","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"key":"853_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021;21:170\u20133.","journal-title":"Clin Med (Lond)"},{"key":"853_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263\u201371.","journal-title":"Lancet"},{"key":"853_CR3","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/acr.23743","volume":"71","author":"L Eder","year":"2019","unstructured":"Eder L, Widdifield J, Rosen CF, et\u00a0al. Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study. Arthritis Care Res (Hoboken). 2019;71:1084\u201391.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"853_CR4","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s13555-021-00518-8","volume":"11","author":"KA Papp","year":"2021","unstructured":"Papp KA, Gniadecki R, Beecker J, et\u00a0al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther (Heidelb). 2021;11:1053\u201364.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"853_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2310\/7750.2011.10066","volume":"15","author":"K Papp","year":"2011","unstructured":"Papp K, Gulliver W, Lynde C, et\u00a0al. Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15:210\u20139.","journal-title":"J Cutan Med Surg"},{"key":"853_CR6","first-page":"1","volume":"1","author":"P Dyrda","year":"2021","unstructured":"Dyrda P, Pant S. Biologics in plaque psoriasis. Can J Health Technol. 2021;1:1\u201359.","journal-title":"Can J Health Technol"},{"key":"853_CR7","unstructured":"(Pr)OTEZLA\u00ae (apremilast tablets), First in a new class of oral treatment, receives health Canada approval for plaque psoriasis: Cision. https:\/\/www.newswire.ca\/news-releases\/protezla-apremilast-tablets-first-in-a-new-class-of-oral-treatment-receives-health-canada-approval-for-plaque-psoriasis-516432131.html. Accessed 21 June 2022."},{"key":"853_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/09546634.2018.1479725","volume":"30","author":"MJ Murage","year":"2019","unstructured":"Murage MJ, Anderson A, Casso D, et\u00a0al. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. J Dermatol Treat. 2019;30:141\u20139.","journal-title":"J Dermatol Treat"},{"key":"853_CR9","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","volume":"135","author":"RB Warren","year":"2015","unstructured":"Warren RB, Smith CH, Yiu ZZN, et\u00a0al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Investig Dermatol. 2015;135:2632\u201340.","journal-title":"J Investig Dermatol"},{"key":"853_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","volume":"74","author":"JA Doshi","year":"2016","unstructured":"Doshi JA, Takeshita J, Pinto L, et\u00a0al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74:1057-65 e4.","journal-title":"J Am Acad Dermatol"},{"key":"853_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14808","volume":"34","author":"B Lockshin","year":"2021","unstructured":"Lockshin B, Cronin A, Harrison RW, et\u00a0al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry. Dermatol Ther. 2021;34: e14808.","journal-title":"Dermatol Ther"},{"key":"853_CR12","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bjd.19701","volume":"184","author":"T Graier","year":"2021","unstructured":"Graier T, Salmhofer W, Jonak C, et\u00a0al. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol. 2021;184:1094\u2013105.","journal-title":"Br J Dermatol"},{"key":"853_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjd.16102","volume":"178","author":"A Egeberg","year":"2018","unstructured":"Egeberg A, Ottosen MB, Gniadecki R, et\u00a0al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178:509\u201319.","journal-title":"Br J Dermatol"},{"key":"853_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et\u00a0al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541\u201351.","journal-title":"Lancet"},{"key":"853_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et\u00a0al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375:345\u201356.","journal-title":"N Engl J Med"},{"key":"853_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","volume":"85","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Lebwohl MG, Mabuchi T, et\u00a0al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85:360\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"853_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","volume":"10","author":"C Leonardi","year":"2020","unstructured":"Leonardi C, Reich K, Foley P, et\u00a0al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther (Heidelb). 2020;10:431\u201347.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"853_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1203475418814229","volume":"23","author":"JR Georgakopoulos","year":"2019","unstructured":"Georgakopoulos JR, Phung M, Ighani A, Yeung J. Ixekizumab (interleukin 17A antagonist): 12-week efficacy and safety outcomes in real-world clinical practice. J Cutan Med Surg. 2019;23:174\u20137.","journal-title":"J Cutan Med Surg"},{"key":"853_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, et\u00a0al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44\u20137.","journal-title":"Value Health"},{"key":"853_CR20","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s13555-021-00627-4","volume":"11","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Shi N, Burge R, et\u00a0al. Comparison of real-world treatment patterns among biologic-experienced patients with psoriasis treated with ixekizumab or secukinumab over 18\u00a0months. Dermatol Ther (Heidelb). 2021;11:2133\u201345.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"853_CR21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2147\/PPA.S233993","volume":"14","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Shi N, Burge R, et\u00a0al. Comparison of real-world treatment patterns among psoriasis patients treated with ixekizumab or adalimumab. Patient Prefer Adherence. 2020;14:517\u201327.","journal-title":"Patient Prefer Adherence"},{"key":"853_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaad.2021.06.878","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Shi N, Somani N, et\u00a0al. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings. J Am Acad Dermatol. 2022;86:581\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"853_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s13555-022-00686-1","volume":"12","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Burge R, Gallo G, et\u00a0al. A retrospective cohort analysis of treatment patterns over 1\u00a0year in patients with psoriasis treated with ixekizumab or guselkumab. Dermatol Ther (Heidelb). 2022;12:701\u201314.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"853_CR24","unstructured":"CADTH Canadian Drug Expert Committee Final Recommendation: Ixekizumab: (Taltz\u2014Eli Lilly Canada Inc): indication: moderate to severe plaque psoriasis. CADTH common drug reviews. Ottawa; 2016."},{"key":"853_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/09546634.2020.1755009","volume":"33","author":"W Gulliver","year":"2020","unstructured":"Gulliver W, Penney M, Power R, et\u00a0al. Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events. J Dermatol Treat. 2020;33:354\u201360.","journal-title":"J Dermatol Treat"},{"key":"853_CR26","first-page":"770","volume":"25","author":"D Brixner","year":"2019","unstructured":"Brixner D, Rubin DT, Mease P, et\u00a0al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J Manag Care Spec Pharm. 2019;25:770\u20139.","journal-title":"J Manag Care Spec Pharm"},{"key":"853_CR27","first-page":"859","volume":"23","author":"DT Rubin","year":"2017","unstructured":"Rubin DT, Mittal M, Davis M, et\u00a0al. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2017;23:859\u201367.","journal-title":"J Manag Care Spec Pharm"},{"key":"853_CR28","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.2147\/PPA.S326498","volume":"15","author":"G Argenziano","year":"2021","unstructured":"Argenziano G, Amerio P, Aragone MG, et\u00a0al. Assessing the beneficial impact of a patient support program in secukinumab-treated patients with psoriasis in Italy. Patient Prefer Adherence. 2021;15:2551\u201362.","journal-title":"Patient Prefer Adherence"},{"key":"853_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","volume":"141","author":"DM Ashcroft","year":"1999","unstructured":"Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141:185\u201391.","journal-title":"Br J Dermatol"},{"key":"853_CR30","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1080\/09546634.2020.1853023","volume":"33","author":"M Shahriari","year":"2022","unstructured":"Shahriari M, Harrison RW, Burge R, et al. Disease response and patient-reported outcomes among initiators of ixekizumab. J Dermatol Treat. 2022;33:1538\u201346.","journal-title":"J Dermatol Treat"},{"key":"853_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"853_CR32","first-page":"882","volume":"27","author":"ME Peter","year":"2021","unstructured":"Peter ME, Zuckerman AD, DeClercq J, et\u00a0al. Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy. J Manag Care Spec Pharm. 2021;27:882\u201390.","journal-title":"J Manag Care Spec Pharm"},{"key":"853_CR33","first-page":"1457","volume":"22","author":"J Harnett","year":"2016","unstructured":"Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. Administrative Claims Database. J Manag Care Spec Pharm. 2016;22:1457\u201371.","journal-title":"J Manag Care Spec Pharm"},{"key":"853_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000488586","volume":"234","author":"A Costanzo","year":"2018","unstructured":"Costanzo A, Malara G, Pelucchi C, et\u00a0al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology. 2018;234:1\u201312.","journal-title":"Dermatology"},{"key":"853_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.12927\/hcpap.2020.26263","volume":"19","author":"WP Wodchis","year":"2020","unstructured":"Wodchis WP, Reid RJ. Improving value means increasing population health and equity. Healthc Pap. 2020;19:10\u20135.","journal-title":"Healthc Pap"},{"key":"853_CR36","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.clinthera.2018.04.017","volume":"40","author":"JK Marshall","year":"2018","unstructured":"Marshall JK, Bessette L, Shear NH, et\u00a0al. Canada\u2019s study of adherence outcomes in patients receiving adalimumab: 3-year results from the COMPANION study. Clin Ther. 2018;40:1024\u201332.","journal-title":"Clin Ther"},{"key":"853_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.clinthera.2018.02.001","volume":"40","author":"JK Marshall","year":"2018","unstructured":"Marshall JK, Bessette L, Thorne C, et\u00a0al. Impact of the adalimumab patient support program\u2019s care coach calls on persistence and adherence in Canada: an observational retrospective cohort study. Clin Ther. 2018;40:415-29 e6.","journal-title":"Clin Ther"},{"key":"853_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40744-018-0109-3","volume":"5","author":"L Bessette","year":"2018","unstructured":"Bessette L, Lebovic G, Millson B, et\u00a0al. Impact of the adalimumab patient support program on clinical outcomes in ankylosing spondylitis: results from the COMPANION study. Rheumatol Ther. 2018;5:75\u201385.","journal-title":"Rheumatol Ther"},{"key":"853_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/jcag\/gwy059","volume":"1","author":"N Narula","year":"2018","unstructured":"Narula N, Millson B, Charland K, et\u00a0al. Impact of adalimumab patient support program\u2019s care coach calls on clinical outcomes in patients with Crohn\u2019s disease in Canada: an observational retrospective cohort study. J Can Assoc Gastroenterol. 2018;1:191\u20138.","journal-title":"J Can Assoc Gastroenterol"},{"key":"853_CR40","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s13555-021-00616-7","volume":"11","author":"M Schmitt-Egenolf","year":"2021","unstructured":"Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykowicz NM, et\u00a0al. Drug persistence of biologic treatments in psoriasis: a Swedish national population study. Dermatol Ther (Heidelb). 2021;11:2107\u201321.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00853-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00853-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00853-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T18:35:51Z","timestamp":1673030151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00853-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["853"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00853-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2022,11,27]]},"assertion":[{"value":"27 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}